As many of you have heard, the FDA put out a report on September 19th regarding the isoxazoline class of drugs including Bravecto (fluralaner). Pet Vet routinely dispenses Bravecto to our patients for control of fleas & ticks.
Below is the statement put out by Merck, the company that makes Bravecto:
The current FDA communication is based on information gathered on the isoxazoline class as a whole and therefore applies to all products in the class, which includes Bravecto.
After over three years of surveillance of more than 80 million Bravecto doses distributed in 85 countries, the overall worldwide reporting rate for neurological signs, including seizures, remains classified as very rare. Very rare is defined by international regulatory authorities as less than 1 in 10,000 incidences.
Every molecule is unique, even within a class, and each has its own safety profile. This is why it’s important for all pet owners to speak to their veterinarian before making a decision about flea and tick control products for their dog.
Nothing is more important to Merck Animal Health than the safety and efficacy of our products and the well-being of animals. We encourage all pet owners to speak to their veterinarian before making a decision about flea and tick control products. More than just a nuisance, fleas and ticks transmit disease and pose animal and human health risks. It is critical to protect pets from these parasites.
As always if you have any questions or concerns please feel free to speak to one of our staff or Contact Us via phone or email.